Following ASCO 2024, Joshua K. Sabari, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the LAURA trial investigating osimertinib following definitive chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer with EGFR mutations.
CNS Activity of Third-Generation ALK TKIs Influence Approach in NSCLC
June 21st 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.
Read More